Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/51039
Full metadata record
DC FieldValueLanguage
dc.contributor.authorT. Puthanakiten_US
dc.contributor.authorG. Jourdainen_US
dc.contributor.authorS. Hongsiriwonen_US
dc.contributor.authorP. Suntarattiwongen_US
dc.contributor.authorK. Chokephaibulkiten_US
dc.contributor.authorV. Sirisanthanaen_US
dc.contributor.authorP. Kosalaraksaen_US
dc.contributor.authorW. Petdachaien_US
dc.contributor.authorR. Hansudewechakulen_US
dc.contributor.authorU. Siangphoeen_US
dc.contributor.authorT. Suwanlerken_US
dc.contributor.authorJ. Ananworanichen_US
dc.date.accessioned2018-09-04T04:50:33Z-
dc.date.available2018-09-04T04:50:33Z-
dc.date.issued2010-10-01en_US
dc.identifier.issn14681293en_US
dc.identifier.issn14642662en_US
dc.identifier.other2-s2.0-77955610006en_US
dc.identifier.other10.1111/j.1468-1293.2010.00828.xen_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77955610006&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/51039-
dc.description.abstractObjectives: The aim of the study was to assess the prevalence, predictors and patterns of genotypic resistance mutations in children after failure of World Health Organization-recommended initial nonnucleoside reverse transcriptase inhibitor (NNRTI)-based treatment regimens. Methods: We carried out a multicentre retrospective study of genotyping tests performed for all HIV-infected children at eight paediatric centres in Thailand who experienced failure of NNRTI therapy at a time when virological monitoring was not routinely available. Results: One hundred and twenty children were included in the study. Their median age (interquartile range) was 9.1 (6.8-11.0) years, the median duration of their NNRTI regimens was 23.7 (15.7-32.6) months, their median CD4 percentage was 12% (4-20%), and their median plasma HIV RNA at the time of genotype testing was 4.8 (4.3-5.2) log10 HIV-1 RNA copies/mL. The nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations found were as follows: 85% of the children had M184V/I, 23% had at least four thymidine analogue mutations, 12% had the Q151M complex, 5% had K65R, and 1% had the 69 insertion. Ninety-eight per cent of the children had at least one NNRTI resistance mutation, and 48% had etravirine mutation-weighted scores ≥4. CD4 percentage <15% prior to switching regimens [odds ratio (OR) 5.49; 95% confidence interval (CI) 2.02-14.93] and plasma HIV RNA>5 log10 copies/mL (OR 2.46; 95% CI 1.04-5.82) were independent predictors of at least four thymidine analogue mutations, the Q151M complex or the 69 insertion. Conclusions: In settings without routine viral load monitoring, second-line antiretroviral therapy regimens should be designed assuming that clinical or immunological failure is associated with high rates of multi-NRTI resistance and NNRTI resistance, including resistance to etravirine. © 2010 British HIV Association.en_US
dc.subjectMedicineen_US
dc.titleHIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapyen_US
dc.typeJournalen_US
article.title.sourcetitleHIV Medicineen_US
article.volume11en_US
article.stream.affiliationsThe HIV Netherlands Australia Thailand Research Collaborationen_US
article.stream.affiliationsChulalongkorn Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsRegional Hospitalen_US
article.stream.affiliationsQueen Sirikit National Institute of Child Healthen_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsKhon Kaen Universityen_US
article.stream.affiliationsPetchburi Hospitalen_US
article.stream.affiliationsChiang Rai Regional Hospitalen_US
article.stream.affiliationsSouth East Asia Research Collaboration with Hawaiien_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.